Pfizer trades up with Rigel’s Veppanu deal done
Pfizer shares edged up 0.15% to $26.04 after Rigel closed a Veppanu licensing deal with Arvinas and Pfizer, triggering a $35 million payment to Pfizer; the deal highlights ongoing investor focus on whether Pfizer’s oncology and obesity pipeline can offset COVID declines and looming patent losses, with analysts split on pipeline potential versus slow growth and patent pressure.